APVO News and Press, Aptevo Therapeutics Inc. From 03/20/19

Unique Mechanism of Action Suppresses Inflammation and Immune Activation  Without Promoting Pro-Inflammatory Lymphocyte Stimulation Preliminary Phase 1 Data Read-outs Anticipated Q3 and Q4 2019 SEATTLE, March 20, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO)...

Aptevo Therapeutics (NASDAQ: APVO ): FY GAAP EPS of -$2.39. More news on: Aptevo Therapeutics Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...

Achieves Record Annual IXINITY ® Net Revenue of $23.1 Million  Representing 111% Increase Over 2017 Advances APVO436 Into Phase 1/1b Clinical Trial for Treatment of  Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome Receives Authorization to Commence ...

Gainers:  Bio-Path Holdings (NASDAQ: BPTH ) +201% . Seelos Therapeutics (NASDAQ: SEEL ) +79% . ArQule (NASDAQ: ARQL ) +66% . Altimmune (NASDAQ: ALT ) +60% . Rosetta Stone (NYSE: RST ) +31% . Calumet Specialty Products Partners (NASDAQ: CLMT ) +29% . Cleveland BioLabs (NASDAQ: CB...

Aptevo Therapeutics ( APVO -45.1% ) slumps on almost 13x higher volume in response to its public offering of 19.85M shares of common stock and warrants to purchase up to the same number of shares at a price of $1.00 per share and warrant. More news on: Aptevo Therapeutics Inc., Healthc...

Aptevo Therapeutics (NASDAQ: APVO )  -38%  on equity offering . More news on: Aptevo Therapeutics Inc., Resideo Technologies, Inc., Kroger Co., Stocks on the move, Read more ...

SEATTLE, March 07, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today announced the pricing of (i) for a combined public offering price of $1.00 per share of common sto...

SEATTLE, March 06, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today announced that it intends to offer and sell, subject to market and other conditions, shares of its...

ADAPTIR™ Bispecific Antibody Candidates Poised to Progress in Clinical Development APVO436 Advancing in Phase 1 Clinical Trial for Acute Myeloid Leukemia; APVO210 Beginning Phase 1 Clinical Trial in Q1 2019; ALG.APV-527 Progressing with CTA Submission in H2 2019 Project...

Provides Opportunistic Capital of up to $35 Million to Aptevo During the 36-month Term of the Agreement SEATTLE, Dec. 21, 2018 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced...